A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides
NCT ID: NCT00134498
Last Updated: 2007-11-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
160 participants
INTERVENTIONAL
2005-02-28
2006-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To assess the safety and efficacy of the fixed combination torcetrapib/atorvastatin in subjects with Fredrickson Type IV Hypertriglyceridemia.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
torcetrapib/atorvastatin
atorvastatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid
* Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
* Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Anaheim, California, United States
Pfizer Investigational Site
Huntington Beach, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Orange, California, United States
Pfizer Investigational Site
Orangevale, California, United States
Pfizer Investigational Site
Pacific Palisades, California, United States
Pfizer Investigational Site
Studio City, California, United States
Pfizer Investigational Site
Tustin, California, United States
Pfizer Investigational Site
Walnut Creek, California, United States
Pfizer Investigational Site
Farmington, Connecticut, United States
Pfizer Investigational Site
Washington D.C., District of Columbia, United States
Pfizer Investigational Site
Hollywood, Florida, United States
Pfizer Investigational Site
Longwood, Florida, United States
Pfizer Investigational Site
West Palm Beach, Florida, United States
Pfizer Investigational Site
Tripler AMC, Hawaii, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Indianapolis, Indiana, United States
Pfizer Investigational Site
Overland Park, Kansas, United States
Pfizer Investigational Site
Baton Rouge, Louisiana, United States
Pfizer Investigational Site
Scarborough, Maine, United States
Pfizer Investigational Site
Bethesda, Maryland, United States
Pfizer Investigational Site
Ann Arbor, Michigan, United States
Pfizer Investigational Site
Canton, Michigan, United States
Pfizer Investigational Site
Portage, Michigan, United States
Pfizer Investigational Site
Richland, Michigan, United States
Pfizer Investigational Site
Saint Cloud, Minnesota, United States
Pfizer Investigational Site
Olive Branch, Mississippi, United States
Pfizer Investigational Site
Jefferson City, Missouri, United States
Pfizer Investigational Site
St Louis, Missouri, United States
Pfizer Investigational Site
Las Vegas, Nevada, United States
Pfizer Investigational Site
Rochester, New York, United States
Pfizer Investigational Site
Syracuse, New York, United States
Pfizer Investigational Site
West Seneca, New York, United States
Pfizer Investigational Site
Statesville, North Carolina, United States
Pfizer Investigational Site
Sellersville, Pennsylvania, United States
Pfizer Investigational Site
Warwick, Rhode Island, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Madison, Wisconsin, United States
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
London, Ontario, Canada
Pfizer Investigational Site
Chicoutimi, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Ste-Foy, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A5091025
Identifier Type: -
Identifier Source: org_study_id